Residency · Residency · Neurology

Drug-Induced Movement Disorders

Overview

Drug-induced movement disorders are among the most common movement disorders encountered in clinical practice. They can present acutely (within minutes to days) or after chronic exposure (months to years). Recognition is critical because many are reversible with drug withdrawal or specific treatment. Most are caused by dopamine receptor blocking agents (DRBAs), including typical and atypical antipsychotics and antiemetics such as metoclopramide and prochlorperazine.

Acute Dystonic Reaction

Clinical Features

Acute dystonic reactions develop within hours to days of initiating or increasing a DRBA. They manifest as sustained involuntary muscle contractions producing abnormal postures. Common patterns include oculogyric crisis (forced upward deviation of the eyes), torticollis, trismus, tongue protrusion, opisthotonos, and laryngospasm (which constitutes a medical emergency). Young males and children are at highest risk. Additional risk factors include high-potency typical antipsychotics, cocaine use, and recent DRBA dose increases.

Management

Diphenhydramine 25-50 mg IV/IM or benztropine 1-2 mg IV/IM provides rapid relief within minutes. Oral anticholinergic therapy should be continued for 48-72 hours to prevent recurrence while the offending drug clears the system. Benzodiazepines (lorazepam) serve as an alternative or adjunct. If the DRBA must be continued, switching to a lower-risk antipsychotic should be considered.

<image>Clinical photographs showing oculogyric crisis, torticollis, and trismus as manifestations of acute dystonic reaction</image>

Drug-Induced Parkinsonism (DIP)

Clinical Features

DIP is the second most common cause of parkinsonism after PD. Unlike PD, it presents with symmetric, bilateral onset and develops weeks to months after starting a DRBA. Tremor may be less prominent than in PD, with postural tremor predominating. "Rabbit syndrome" (perioral tremor) is more specific to DIP than to PD.

Causative Agents

Typical antipsychotics (haloperidol, chlorpromazine) carry greater risk than atypical antipsychotics. Quetiapine and clozapine have the lowest DIP risk among antipsychotics. Metoclopramide is the most common non-psychiatric cause. Calcium channel blockers (flunarizine, cinnarizine) are common causes in some countries. Valproic acid, lithium, and SSRIs are rare causes.

Diagnostic Considerations

DaTscan is normal in pure DIP (the dopamine transporter is intact) versus reduced in PD. However, DRBAs can unmask subclinical PD; if parkinsonism persists more than 6 months after drug withdrawal, underlying PD should be considered.

Management

The offending agent should be discontinued or reduced if possible. When an antipsychotic is essential, switching to quetiapine or clozapine is recommended. Amantadine may provide symptomatic benefit. Anticholinergics (trihexyphenidyl) may help but carry cognitive risk in the elderly. Levodopa is generally ineffective in true DIP.

Tardive Dyskinesia (TD)

Clinical Features

TD develops after chronic exposure to DRBAs, typically over months to years. The classic presentation consists of stereotyped, repetitive orofacial movements including tongue protrusion, lip smacking, chewing, and grimacing. It may also affect the trunk (rocking), limbs (choreiform movements), and respiratory muscles. TD can persist even after the offending drug is discontinued and may be irreversible.

Risk Factors

Risk increases with older age, female sex, longer duration of DRBA use, higher cumulative doses, diabetes, mood disorders, prior acute dystonic reaction, and African American ancestry.

Pathophysiology

The proposed mechanism involves dopamine receptor supersensitivity from chronic blockade, striatal maladaptive plasticity, and impaired GABAergic inhibition.

VMAT2 Inhibitors (First-Line Treatment)

Valbenazine (Ingrezza) is FDA-approved for TD, given once daily starting at 40 mg and increasing to 80 mg. Deutetrabenazine (Austedo) is also FDA-approved for TD, given twice daily with CYP2D6 metabolizer status considered. Both reduce presynaptic dopamine release by inhibiting vesicular monoamine transporter 2 and show significant improvement in AIMS scores in randomized trials. Side effects include sedation, depression (careful screening required), parkinsonism, and akathisia. They are contraindicated in hepatic impairment and in patients taking MAO inhibitors.

Other Management Strategies

The offending DRBA should be discontinued if clinically safe, though TD may transiently worsen before improving. Abrupt antipsychotic discontinuation should be avoided due to risk of withdrawal-emergent dyskinesia and psychotic relapse. Switching to clozapine or quetiapine reduces TD risk and may improve existing TD. Clonazepam provides modest adjunctive benefit. GPi DBS has been reported in case series for severe refractory TD.

Tardive Dystonia

Tardive dystonia manifests as sustained dystonic postures (retrocollis, trunk extension, limb dystonia) and typically affects younger patients compared to classic orofacial TD. It is often more disabling and may respond to botulinum toxin, VMAT2 inhibitors, anticholinergics, or DBS.

<image>AIMS (Abnormal Involuntary Movement Scale) examination diagram showing the 12-item assessment areas for monitoring tardive dyskinesia</image>

Neuroleptic Malignant Syndrome (NMS)

Clinical Features

The classic tetrad consists of hyperthermia (often exceeding 40 degrees C), muscular rigidity ("lead-pipe"), altered mental status, and autonomic instability (tachycardia, labile blood pressure, diaphoresis). Onset occurs days to weeks after starting or increasing a DRBA, or after withdrawal of dopaminergic medications in PD patients. Laboratory findings include massively elevated CK (often above 1000 IU/L), leukocytosis, elevated transaminases, metabolic acidosis, and myoglobinuria. Mortality is 5-10% with modern management.

Differential Diagnosis

Serotonin syndrome features more prominent clonus and hyperreflexia with less severe rigidity. Malignant hyperthermia occurs in the intraoperative setting with halogenated anesthetics or succinylcholine. Lethal catatonia, heatstroke, CNS infection, and thyroid storm must also be considered.

Management

All DRBAs are stopped immediately (or dopaminergic medications restarted in PD patients). Supportive care includes ICU admission, aggressive IV hydration, cooling measures, and monitoring for rhabdomyolysis and renal failure. Specific therapies include dantrolene (1-2.5 mg/kg IV, a direct muscle relaxant that reduces rigidity and hyperthermia) and bromocriptine (2.5-5 mg PO/NG every 8 hours, a dopamine agonist to restore dopaminergic tone). Amantadine is an alternative dopaminergic agent. Treatment should continue for at least 10 days (longer if a depot antipsychotic was used). If antipsychotic rechallenge is needed, clinicians should wait at least 2 weeks and use a low-potency or atypical agent (clozapine or quetiapine) at the lowest dose.

<image>Diagnostic algorithm for differentiating neuroleptic malignant syndrome from serotonin syndrome based on clinical features, medication history, and examination findings</image>

Serotonin Syndrome

Clinical Features

The clinical triad consists of altered mental status, autonomic dysfunction, and neuromuscular excitability. Key neuromuscular findings include clonus (spontaneous, inducible, and ocular), hyperreflexia, myoclonus, tremor, and hypertonicity predominantly in the lower limbs. Onset is usually within 24 hours of a serotonergic medication change. The Hunter Criteria provide the most validated diagnostic framework: the presence of a serotonergic agent plus at least one of spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor plus hyperreflexia, or hypertonia plus temperature above 38 degrees C plus ocular or inducible clonus.

Causative Agents

Common culprits include SSRIs, SNRIs, MAO inhibitors (the most dangerous combinations), tramadol, meperidine, fentanyl, triptans (mild risk in practice despite theoretical concern), linezolid (a weak MAO inhibitor), methylene blue (also an MAO inhibitor), dextromethorphan, St. John's wort, and MDMA.

Key Differentiating Features from NMS

Serotonin syndrome has rapid onset (hours) versus gradual onset (days) in NMS. Neuromuscular findings favor clonus and hyperreflexia in serotonin syndrome versus lead-pipe rigidity in NMS. Pupils are mydriatic in serotonin syndrome versus normal in NMS. Diarrhea and hyperactive bowel sounds are common in serotonin syndrome but not NMS. CK is modestly elevated or normal in serotonin syndrome versus massively elevated in NMS.

Management

All serotonergic agents are discontinued. Supportive care includes IV fluids, cooling, and benzodiazepines for agitation and myoclonus. Cyproheptadine, a serotonin antagonist, is given as a 12 mg loading dose followed by 2 mg every 2 hours (only available orally or via NG tube). Most cases resolve within 24-72 hours with drug withdrawal. Physical restraints should be avoided because they can worsen hyperthermia from isometric muscle contraction.

Akathisia

Clinical Features

Akathisia produces a subjective sense of inner restlessness with an inability to remain still. Objective signs include repetitive movements such as rocking, shifting weight, crossing and uncrossing legs, and marching in place. It can be acute (within days of starting a DRBA), tardive (after months), or withdrawal-associated. It is one of the most distressing drug side effects and is associated with suicidality.

Management

The offending agent should be reduced or switched. Propranolol (30-120 mg/day) is the most effective pharmacotherapy. Benzodiazepines serve an adjunctive role. Mirtazapine may help through 5-HT2A antagonism. Anticholinergics are less effective than in DIP.

Clinical Pearls

Always ask about antiemetic use (metoclopramide, prochlorperazine) when evaluating new-onset parkinsonism; patients and referring physicians often do not consider these as causative. The distinction between NMS and serotonin syndrome is clinically critical because treatments differ: NMS requires dopamine agonists while serotonin syndrome requires serotonin antagonists. DaTscan can help distinguish DIP from PD when parkinsonism persists after drug withdrawal, but a normal DaTscan in a patient on a DRBA does not exclude future development of PD. VMAT2 inhibitors are the only FDA-approved treatments for tardive dyskinesia; AIMS assessment should be performed regularly in all patients on chronic DRBAs. Abrupt DRBA discontinuation can cause withdrawal-emergent dyskinesia (usually self-limited within weeks), so gradual tapering is preferred. Clozapine and quetiapine are the preferred antipsychotics when parkinsonism, TD, or NMS risk is a concern. In PD patients, abrupt cessation of dopaminergic medications during hospitalization can precipitate a syndrome identical to NMS ("parkinsonism-hyperpyrexia syndrome"); dopaminergic drugs must be continued perioperatively.

References

• Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785-794.
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):468-475.
• Velamoor VR. Neuroleptic malignant syndrome: recognition, prevention and management. Drug Saf. 1998;19(1):73-82.
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
• Duma SR, Fung VSC. Drug-induced movement disorders. Aust Prescr. 2019;42(2):56-61.

Read this lecture as Markdown